“…As our knowledge of cancer biology improves and new approaches to treatment and diagnosis develop, the management of cancer patients will continue to change substantially. The identification of new biomarkers is increasingly supporting the development of targeted drugs, which pose crucial challenges for the daily practice: Who will really benefit from them? Can we manage all possible side-effects? Are these new drugs affordable? How can we best respond and adapt to new and emerging treatment approaches and paradigms? These are just some of the many questions that will be addressed during our discussions at ESMO 2012, with state-of-the-art education and best practices, presentations and conversations with top experts from various disciplines, controversial debates and, of course, the very latest cutting-edge research..." ...read more